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Surgical management can be delayed by pancytopenia or other
complications of PSCT. Transsphenoidal surgery has been shown
to be more successful in improving vision if performed within 8
days of diagnosis. Emergent surgery is indicated for deteriorating
vision, hemiparesis, or altered consciousness, while those with sta-
ble or resolving visual field deficits can be managed conservatively.
Our patient was managed conservatively until engraftment. Trans-
sphenoidal surgery was then performed, 9 days after diagnosis. At
six months follow-up, his visual deficits had resolved but he contin-
ued to have diabetes insipidus.
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AUGMENTATION OF STANDARD UMBILICAL CORD BLOOD TRANSPLAN-
TATIONWITH ALDHbr CELLS: RESULTS OF A PHASE I STUDY IN PEDIAT-
RIC PATIENTS
Kurtzberg, J.1, Mendizabal, A.2, Carter, S.2, Reese, M.1, Kaestner, A.1,
Hickerson, D.3, Winstead, L.3, Fiordalisi, M.3, Waters-Pick, B.1,
Balber, A.3 1Duke University Medical Center, Durham, NC; 2The
EMMES Corporation, Rockville, MD; 3Aldagen, Durham, NC.
Transplantation of unrelated donor umbilical cord blood (UCB)
is limited by graft failure and engraftment delays. Strategies to facil-
iate engraftment are needed. Cord blood contains a population
(0.5%) of cells expressing aldehyde dehydrogenase (ALDHbr), an
intracellular enzyme highly enriched in hematopoietic stem and
progenitor cells. The primary endogenous substrates for ALDH
are retinaldehydes, oxidized to retinoic acid, which exert major ef-
fects on hematopoiesis. We hypothesized that augmentation of
a standard UCB transplant with ALDHbr cells isolated from a por-
tion of the graft would improve engraftment. Over the past 2 years,
21 pediatric patients with malignant (n5 7) and metabolic (n5 14)
disorders prepared with myeloablative preparative regimens were
transplantedwith aUCBunit cryopreserved in a compartmentalized
bag allowing for 80% of the unit to be administered as a conven-
tional graft and 20% as purified ALDHbr cells, freshly isolated (n
5 8) or primed with cytokines 5 days (n5 13). Neither infusional
toxicity nor an increase in unexpected adverse events were observed.
The cumulative incidences (CI) of neutrophil (ANC 500 by day 42)
and platelet engraftment (Platelets 50 k by day 180) were 92.9%
(95% CI 73.1–100.0) and 73.1 (95%CI 41.7–100.0). These results
were compared to a control group from the COBLT study, which
contained similar patients (although it was not possible to match
all characteristics between the 2 groups), where the CI of neutrophil
and platelet engraftment were 77.9% (95% CI 67.9–87.9) and
64.9% (95% CI 51.6–78.2). These differences favored patients
transplanted with ALDHbr cells at p5 0.01 and p5 0.02. Neutro-
phil engraftment occurred in a median of 19 versus 26 days in the
ALDH versus COBLT patients. Platelet engraftment was acceler-
ated to 58 days in the ALDH patients compared to 107 days in
the COBLT patients. Significant accelerations in neutrophil and
platelet engraftment were also observed in a subgroup analysis of
metabolic patients alone. There were no differences seen between
groups receiving freshly sorted versus primed ALDHbr cells. While
preliminary, these results suggest that the infusion of ALDHbr cells
facilitates overall engraftment, perhaps through a niche effect. Fur-
ther investigation of mechanisms of action and a phase II study are
underway.
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PHASE 1 TRIAL OF AUTOLOGOUS BONEMARROWMESENCHYMAL STEM
CELL TRANSPLANTATION IN PATIENTS WITH DECOMPENSATED LIVER
CIRRHOSIS
Alimoghaddam, K.1, Mohamadnejad, M.2, Mohyedin Bonab, M.1,
Bagheri, M.2, Bashtar, M.1, Ghanati, H.3, Ghavamzadeh, A.1,
Malekzadeh, R.1 1University of Tehran/Medical Sciences, Tehran, Is-
lamic Republic of Iran; 2Digestive Disease Research Center of University
of Tehran/Medical Sciences, Tehran, Islamic Republic of Iran; 3Univer-
sity of Tehran/Medical Sciences, Tehran, Islamic Republic of Iran.
Background: The standard treatment for decompensated liver
cirrhosis is liver transplantation. However, it has several limitations.
Recent animal studies suggest that bone marrow stem cell trans-
plantation can lead to regression of liver fibrosis. The objective of
this study was to determine the safety and feasibility of autologous
bone marrow-mesenchymal stem cell transplantation in patients
with decompensated liver cirrhosis.Methods: In this phase 1 trial,
four patients with decompensated liver cirrhosis were included.
Their bone marrow was aspirated, mesenchymal stem cells were
cultured, and a mean 31.73  106 mesenchymal stem cells were in-
fused through a peripheral vein. Primary outcomes were evaluating
the safety and feasibility of the work. Secondary outcomes were
evaluating changes in the model for end-stage liver disease score,
and the quality of life of the patients. Results: There were no
side-effects in the patients during follow-up. The model for end-
stage liver disease scores of patients 1, and 4 improved by four
and three points, respectively by the end of follow-up. Furthermore,
the quality of life of all four patients improved by the end of follow-
up. Using SF-36 questionnaire, the mean physical component scale
increased from 31.44 to 65.19, and the mean mental component
scale increased from 36.32 to 65.55. Conclusion: Mesenchymal
stem cell transplantation seems to be feasible and safe in the treat-
ment of decompensated liver cirrhosis.
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POST THAW COLONY FORMING UNITS (CFU) IS A STRONG INDEPEN-
DENT PREDICTOR OF ENGRAFTMENT AFTER UNRELATED DONOR UM-
BILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Page, K.M.1, Mendizabal, A.2, Waters-Pick, B.1, Avrutsky, S.1,
Reese, M.1, Prasad, V.K.1, Kurtzberg, J.1 1Duke University Medical
Center, Durham, NC; 2Rockland, MD.
Background: Unrelated donor umbilical cord blood has in-
creased access to transplant for patients lacking matched donors.
However, a non-engraftment rate of approximately 20% despite ad-
equate total nucleated cell (TNC) dose remains a barrier to it’s
overall success. We hypothesized that certain properties of the
UCB graft would be predictive of engraftment.Methods:We per-
formed a retrospective analysis of 423 unrelated donor umbilical
cord blood transplants (UCBT) performed at Duke between 2/
11/2000 and 5/1/2007. Eligible units were required to have pre-
cryopreservation (pre-cryo) data for TNC, CD34 1/- CFU. The
units were obtained from 16 US public cord blood banks and
were selected for transplantation by pre-cryo cell dose and HLA
matching. Pre-cryo data was provided by the cord blood bank as
part of routine banking practices. All units were thawed and washed
in the Duke Stem Cell Laboratory before transplant. Post-thaw
testing (TNC, viability, CD34, CFU) was performed by consistent
personnel. Univariate and multivariate analyses were performed to
identify significant pre-cryo, post-thaw, and baseline factors predic-
tive of neutrophil and platelet engraftment. Results: Patients in the
cohort were characterized as follows: 68% had malignancies, 61%
males, 73% Caucasian and 38% CMV1. Graft/patient mismatch-
ing was present for HLA (93%), sex (50%) and race (24%). There
was excellent correlation between pre-cryo and post-thaw TNC
(r2 5 0.92) and CD34 (r2 5 0.68) content, but much weaker corre-
lation for CFUs (r2 5 0.27). In univariate analysis, pre-cryo/
post-thaw CD34 (larger) and pre-cryo/post-thaw CFU (larger),
pre-cryo/post-thaw TNC (larger), age (#5 years), disease (non-
malignant), weight (#12 kg), CMV status (negative), recipient
ethnicity (Caucasian), HLA match (5/6 or 6/6) were predictive of
neutrophil and platelet engraftment. In the overall multivariate
analysis of neutrophil engraftment, larger post-thaw CFU
(\0.0001), larger post-thaw CD34 (p 5 0.02), Male units (p 5
0.01), 5/6 or 6/6 HLAmatch (p5 0.02) were significant. For plate-
let engraftment, larger post-thaw CFU (p 5 0.002) and Caucasian
recipients (p 5 0.006) were predictive. Conclusions: Post-thaw
CFUs are a strong independent laboratory predictor of neutrophil
and platelet engraftment after UCBT. Efforts should be focused
on developing a reproducible assay on CBU segments that would
correlate with results obtained at thaw of the UCB unit and thus
serve as a potency assay before UCB release from the bank.
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STEM CELL RECOVERY FOLLOWING IMPLEMENTATION OF AN AUTO-
MATED CORD BLOOD PROCESSING SYSTEM IN A HIGH VOLUME LABO-
RATORY
Rosenthal, J.1, Brown, H.L.2, Harris, D.T.3 1City of Hope, Duarte, CA;
2CBR Systems, Inc., San Bruno, CA; 3University of Arizona, Tucson,
AZ.
Background: Many cord blood unit (CBU) processing facilities
are transitioning to automated systems to standardize methods
and decrease human error. The AutoXpress Platform (AXP)
is an automated, functionally closed, sterile CBUprocessing system.
When placedwithin the AXP device and centrifuged, whole blood is
separated into composite cell populations and the TNC fraction is
separated and automatically delivered into a blow-molded freezing
bag at a uniform volume of 21 mL.Objective:This study evaluated
the use of the AXP system in a directed donation family cord blood
bank, targeted at producing consistently high TNC and MNC re-
covery rates regardless of variability in collection volume.
Methods: CBU were collected between 12/5/2006 and 2/24/2007
from 1414 consenting mothers who elected to preserve and bank
CBU at Cord Blood Registry (CBR). Collection kits were provided
at enrollment, and after delivery, cord blood was collected from the
umbilical cord and transported to CBR’s processing facility in Tuc-
son, Arizona. During the study period, CBU arriving at the CBR
laboratory were allocated to either ficoll or AXP processing based
on the volume, age, and the degree of clotting. Units processed us-
ing AXP had a volume of 40–130 mL, an age of less than 48 hours
since collection, and a clotting score of 0 to 21 (based on an internal
scale). TNC andMNCwere measured both pre- and post-process-
ing, using the Sysmex analyzer. Results:The mean age of CBU ar-
riving at the laboratory was 23.59 hours, and the mean collection
volume was 72.93 mL (618.10 mL). The mean TNC count post-
processing was 9.94  108, the TNC percent recovery was
96.19%, and the mean MNC percent recovery was 98.65%. Con-
clusions: AXP automated processing provides consistently high
TNC and MNC recovery rates, which has important implications
for stem cell dose if the sample is used in transplant. Because limited
cell dose is frequently cited as an obstacle to CBU transplantation,
processing results could impact the usability of each sample. Be-
cause family cord blood banks process all samples, regardless of col-
lection volume, percent recovery becomes particularly important in
evaluating the differences between processing centers. The AXP
system yields the highest published cell recovery rate to date and
can be easily integrated into a CBU processing center such that it
decreases the labor and time required for CBU processing while
maintaining MNC recovery of greater than 98%.
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IgH GENE REARRANGEMENTS IN PBPC MONONUCLEAR CELLS DOES
NOT INFLUENCE SURVIVAL OR RELAPSE FOLLOWING AUTOLOGOUS
TRANSPLANTATION FOR B-CELL LYMPHOPROLIFERATIVE DISEASES
Ho, J.1, Yang, L.2, Benihashemi, B.1, Martin, L.2, Halpenny, M.2,
McDiarmid, S.1, Huebsch, L.1, Sabloff, M.1, Atkins, H.1, Bence-
Bruckler, I.1, Giulivi, A.2, Allan, D.1 1University of Ottawa, Ottawa,
ON, Canada; 2Canadian Blood Services, Ottawa, ON, Canada.
Background: Relapsed disease remains a major obstacle follow-
ing autologous hematopoietic stem cell transplantation (HSCT) for
non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Studies regarding the role of residual tumour cells collected in au-
tografts in earlier relapse and reduced survival have been inconclu-
sive. The impact of residual disease detected by sensitive molecular
methods in autologous PBPCs remains uncertain and is addressed
in this study. Methods: Patients undergoing autologous HSCT
forNHL andMMat our institution between June 2001 and January
2006 were enrolled (n 5 158). Aliquots of freshly collected PBPC
collections were assessed for the presence of clonal IgH gene rear-
rangements using qualitative semi-nested PCR. Patients with de-
tectable clonal IgH gene rearrangements were designated
‘‘positive’’ and compared with ‘‘negative’’ patients without detect-
able IgH gene rearrangements. Survival, progression-free survival,
and time to next treatment were determined for all patients. All out-
comes were compared using the method of Kaplan and Meier.
Results: In comparison to patients with ‘‘positive’’ PBPC grafts,
patients ‘‘negative’’ for detectable disease had no improvement in
overall survival forMM (p5 0.91) and forNHL (p5 0.82). Further
analysis based on tissue histology in patients with NHL revealed no
significant difference in overall survival between patients with ‘‘pos-
itive’’ grafts comparedwith ‘‘negative’’ PBPC collections (aggressive
histologyNHL, p5 0.74; indolentNHL, p5 0.29). There was also
no significant improvement in progression-free survival among pa-
tients with NHL (p 5 0.85) or MM (p 5 0.91). Conclusion: The
use of autologous PBPCs ‘‘negative’’ for contaminating tumour cells
does not lead to improved overall survival inMMorNHL. Further-
more, the absence of detectable clonal IgH rearrangements using
sensitive PCR did not correlate with a reduction in progression-
free survival. Our results suggest that disease relapse cannot be ad-
equately explained by the reinfusion of PBPCs containing residual
tumour cells. It is possible that high dose chemotherapy regimens
used in autologous HSCT are not sufficiently eliminating residual
tumour burden in some patients, including those with ‘‘negative’’
PBPC collections. Taken together, our results suggest that strate-
gies aimed at removing tumour cells from autologous PBPC grafts
in patients with MM and NHL may have marginal benefit.
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ENHANCED NATURAL KILLER (NK) AND NK T CELL ACTIVATION, EX-
PANSION AND CYTOKINE PROTEIN PRODUCTION FOLLOWING EX-
VIVO ENGINEERING (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB): POTENTIAL FOR CB NK AND NK T CELLS IN ADOPTIVE
CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J., Sugarman, E., Day, N., Hochberg, J., Mar, B., Cairo, E., van
de Ven, C., Cairo, M.S. Columbia University, New York, NY.
CB is limited by the absence of available donor effector cells fol-
lowing UCBT.We demonstrated the immaturity of CB by reduced
Table 1. Factors Predictive of Neutrophil and Platelet Engraftment in
Multivariate Analysis of Graft/Recipient Characteristics
Multivariate Model
Neutrophil
engraftment
(p-value)
Platelet
engraftment
(p-value)
Pre-cryopreservation CD341 (0.0046) Recipient ethnicity
(0.0052)
Recipient CMV
(0.0138)
TNC (0.0173)
CFU (0.0337) CFU (0.0324)
Unit Sex (0.0393)
Post-thaw CFU (\0.0001) CFU (\0.0001)
CD34 (0.0013) HLA match (0.0117)
HLA match
(0.0065)
Recipient ethnicity
(0.0135)
Overall Post thaw CFU
(\0.0001)
Recipient ethnicity
(0.0063)
Unit Sex (0.0131) Post thaw CFU (0.002)
HLA match (0.0186)
Post thaw CD34 (0.02)
AXP Stem Cell Recovery
Volume
(mL)
Mean Post-
Processing
TNC
(108)
TNC
Percent
Recovery
(%)
Mean Post-
Processing
MNC
(108)
MNC
Percent
Recovery
(%)
Mean 72.93 9.94 96.19 4.05 98.65
Standard
Deviation
18.10 4.43 11.87 1.59 9.16
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